Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy.

Humans Hypoxia / therapy Nanoparticles Neoplasms / drug therapy Oxygen / therapeutic use Photochemotherapy Tumor Hypoxia
Cancer therapy Nanoparticles Oxygen Tumor hypoxia

Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
10 03 2020
Historique:
received: 26 09 2019
revised: 12 12 2019
accepted: 16 12 2019
pubmed: 22 12 2019
medline: 22 6 2021
entrez: 22 12 2019
Statut: ppublish

Résumé

Tumor hypoxia is a characteristic hallmark of malignant solid tumors, which remains an essential impediment to many current treatments like chemotherapy, radiotherapy, photodynamic therapy and immunotherapy, thereby leading to poor clinical prognosis after therapy. Rationally, modulating tumor hypoxia can be of great interest to augment the therapeutic efficacy of these treatments. In this review, we focus our discussion on current advances in nanoparticles-mediated tumor reoxygenation strategy for relieving tumor hypoxia to improve the therapeutic efficacy of versatile therapies. These nanoparticles can improve tumor oxygen levels via nanoparticles-mediated oxygen-carrying or oxygen-generating tactics to synergize the effectiveness of many current therapeutic modalities. Based on these considerable summaries and analyses, we propose some feasible perspectives on nanoparticles-based tumor reoxygenations to ameliorate the therapeutic outcomes.

Identifiants

DOI: 10.1016/j.jconrel.2019.12.028 PMID: 31862359
pubmed: 31862359
pii: S0168-3659(19)30747-3
doi: 10.1016/j.jconrel.2019.12.028
pii:
doi:

Substances chimiques

Oxygen S88TT14065

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

25-45

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Hong Wang (H)

State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.

Jie Li (J)

State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.

Yuqi Wang (Y)

State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Xiang Gong (X)

State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.

Xiaoxuan Xu (X)

State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.

Jiaoying Wang (J)

State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Yaping Li (Y)

State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Pharmacy, Yantai University, Shandong 264000, China. Electronic address: ypli@simm.ac.cn.

Xianyi Sha (X)

School of Pharmacy, Fudan University, Shanghai 201203, China.

Zhiwen Zhang (Z)

State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Shandong 264000, China. Electronic address: zwzhang0125@simm.ac.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Nanoparticles-mediated reoxygenation strategy...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Signes et symptômes respiratoires › Hypoxie › Nanoparticles-mediated reoxygenation strategy...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Nanoparticles-mediated reoxygenation strategy...
questionsmedicales.fr › Tumeurs › Nanoparticles-mediated reoxygenation strategy...
questionsmedicales.fr › Produits chimiques inorganiques › Gaz › Oxygène › Nanoparticles-mediated reoxygenation strategy...
questionsmedicales.fr › Thérapeutique › Photothérapie › Photothérapie dynamique › Nanoparticles-mediated reoxygenation strategy...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Respiration cellulaire › Hypoxie cellulaire › Hypoxie tumorale › Nanoparticles-mediated reoxygenation strategy...